Fabrication of Electrochemical Biosensor for Detection of Full-Length Tau Protein through Biotin-Streptavidin on Gold Surface

2021 ◽  
Vol MA2021-01 (55) ◽  
pp. 1370-1370
Author(s):  
William Wallace ◽  
Sanela Martic
Vaccines ◽  
2020 ◽  
Vol 8 (1) ◽  
pp. 127
Author(s):  
Juan García-Arriaza ◽  
María Q. Marín ◽  
Jesús Merchán-Rubira ◽  
Sara M. Mascaraque ◽  
Miguel Medina ◽  
...  

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by a progressive memory loss and cognitive decline that has been associated with an accumulation in the brain of intracellular neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau protein, and extracellular senile plaques formed by β-amyloid peptides. Currently, there is no cure for AD and after the failure of anti β-amyloid therapies, active and passive tau immunotherapeutic approaches have been developed in order to prevent, reduce or ideally reverse the disease. Vaccination is one of the most effective approaches to prevent diseases and poxviruses, particularly modified vaccinia virus Ankara (MVA), are one of the most promising viral vectors used as vaccines against several human diseases. Thus, we present here the generation and characterization of the first MVA vectors expressing human tau genes; the full-length 4R2N tau protein or a 3RC tau fragment containing 3 tubulin-binding motifs and the C-terminal region (termed MVA-Tau4R2N and MVA-Tau3RC, respectively). Both MVA-Tau recombinant viruses efficiently expressed the human tau 4R2N or 3RC proteins in cultured cells, being detected in the cytoplasm of infected cells and co-localized with tubulin. These MVA-Tau vaccines impacted the innate immune responses with a differential recruitment of innate immune cells to the peritoneal cavity of infected mice. However, no tau-specific T cell or humoral immune responses were detected in vaccinated mice. Immunization of transgenic P301S mice, a mouse model for tauopathies, with a DNA-Tau prime/MVA-Tau boost approach showed no significant differences in the hyperphosphorylation of tau, motor capacity and survival rate, when compared to non-vaccinated mice. These findings showed that a well-established and potent protocol of T and B cell activation based on DNA/MVA prime/boost regimens using DNA and MVA vectors expressing tau full-length 4R2N or 3RC proteins is not sufficient to trigger tau-specific T and B cell immune responses and to induce a protective effect against tauopathy in this P301S murine model. In the pursuit of AD vaccines, our results highlight the need for novel optimized tau immunogens and additional modes of presentation of tau protein to the immune system.


2017 ◽  
Vol 92 ◽  
pp. 482-488 ◽  
Author(s):  
Scarlet Xiaoyan Wang ◽  
Desiree Acha ◽  
Ajit J. Shah ◽  
Frank Hills ◽  
Ivan Roitt ◽  
...  

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Emily Hill ◽  
Thomas K. Karikari ◽  
Juan Lantero-Rodriguez ◽  
Henrik Zetterberg ◽  
Kaj Blennow ◽  
...  

AbstractTau protein is involved in maintaining neuronal structure. In Alzheimer’s disease, small numbers of tau molecules can aggregate to form oligomers. However, how these oligomers produce changes in neuronal function remains unclear. Previously, oligomers made from full-length human tau were found to have multiple effects on neuronal properties. Here we have cut the tau molecule into two parts: the first 123 amino acids and the remaining 124-441 amino acids. These truncated tau molecules had specific effects on neuronal properties, allowing us to assign the actions of full-length tau to different regions of the molecule. We identified one key target for the effects of tau, the voltage gated sodium channel, which could account for the effects of tau on the action potential. By truncating the tau molecule, we have probed the mechanisms that underlie tau dysfunction, and this increased understanding of tau’s pathological actions will build towards developing future tau-targeting therapies.


FEBS Letters ◽  
1994 ◽  
Vol 337 (2) ◽  
pp. 135-138 ◽  
Author(s):  
R.A. Crowther ◽  
O.F. Olesen ◽  
M.J. Smith ◽  
R. Jakes ◽  
M. Goedert
Keyword(s):  

2021 ◽  
Author(s):  
Sara Rodrigues ◽  
Marta Anglada-Huguet ◽  
Katja Hochgräfe ◽  
Senthilvelrajan Kaniyappan ◽  
Susanne Wegmann ◽  
...  

Abstract Background: The stereotypical progression of Tau pathology during Alzheimer disease has been attributed to trans-neuronal spreading of misfolded Tau proteins, followed by prion-like templated aggregation of Tau. The nature of Tau and the cellular mechanisms of Tau spreading are still under debate. We hypothesized that Tau's propensity for aggregation would correlate with its ability to spread across synapses and propagate pathology.Methods: To study the progressive propagation of Tau proteins in brain regions relevant for Alzheimer disease, we used mice expressing near-physiological levels of full-length human Tau protein carrying pro-aggregant (TauΔK280, TauΔK) or anti-aggregant (TauΔK280-PP, TauΔK-PP) mutations in the entorhinal cortex (EC). To enhance Tau expression in the EC, we performed EC injections of adeno-associated virus (AAV) particles encoding TauΔK or TauΔK-PP. The brains of injected and non-injected EC/TauΔK and EC/TauΔK-PP mice were studied by immunohistological and biochemical techniques to detect Tau propagation to dentate gyrus (DG) neurons and Tau-induced pathological changes.Results: Pro- and anti-aggregant mice had comparable low transgene expression (~0.2-times endogenous mouse Tau). They accumulated human Tau at similar rates and only in expressing EC neurons, including their axonal projections of the perforant path and presynaptic terminals in the molecular layer of the DG. Pro-aggregant EC/TauΔK mice showed misfolded Tau and synaptic protein alterations in EC neurons, not observed in anti-aggregant EC/TauΔK-PP mice. Additional AAV-mediated expression of TauΔK or TauΔK-PP in EC/TauΔK or EC/TauΔK-PP mice, resp., increased the human Tau expression to ~0.65-times endogenous mouse Tau, with comparable spreading of TauΔK and TauΔK-PP throughout the EC. There was a low level of transcellular propagation of Tau protein, without pathological phosphorylation or misfolding, as judged by diagnostic antibodies. Additionally, TauΔK but not TauΔK-PP expression induced hippocampal astrogliosis.Conclusions: Low levels of pro- or anti-aggregant full-length Tau show equivalent distributions in EC neurons, independent of their aggregation propensity. Increasing the expression via AAV induce local Tau misfolding in the EC neurons, synaptotoxicity, and astrogliosis, and lead to a low level of detectable trans-neuronal spreading of Tau. This depends on its concentration in the EC, but, contrary to expectations, does not depend on Tau's aggregation propensity/misfolding, and does not lead to templated misfolding in recipient neurons.


The Analyst ◽  
2014 ◽  
Vol 139 (11) ◽  
pp. 2823-2831 ◽  
Author(s):  
Jose O. Esteves-Villanueva ◽  
Hanna Trzeciakiewicz ◽  
Sanela Martic

Tau–tau binding induced electrostatic and conformational changes on the surface modulating the charge transfer resistance.


Sign in / Sign up

Export Citation Format

Share Document